A Phase 4, Randomized, Open-label, Three-arm Study to Evaluate Implementation Strategies for the Delivery of CAB for HIV Pre-exposure Prophylaxis (PrEP) Across Clinical Settings for Adult (≥18 Years) Black cis-and Transgender Women Without HIV Infection Living in the United States Ending the Epidemic (EHE) Territories
Latest Information Update: 25 Feb 2025
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms EBONI
- Sponsors ViiV Healthcare
Most Recent Events
- 19 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 30 May 2024 Planned End Date changed from 30 May 2025 to 30 Sep 2025.
- 30 May 2024 Planned primary completion date changed from 30 May 2025 to 30 Sep 2025.